Core Insights - Bitcoin is attempting to recover after experiencing its fourth weekly loss in five weeks, currently trading above 105,000, reflecting a 1% increase [1] - Coinbase has been added to investment positions, with a 1% stake initially and an additional 50 basis points following strong earnings, which showed a 44% year-over-year growth in stablecoin revenues and over 400% growth in overall earnings [2] - The potential end of the government shutdown may lead to increased SEC activity regarding crypto regulations, with Coinbase's CEO actively engaging in discussions in Washington, D.C. [2] Company Insights - Coinbase's earnings report indicates significant growth, particularly in stablecoin revenues, suggesting a strong performance in the crypto market [2] - The unwinding of Jim Chanos's short position in the crypto treasury company Strategy indicates a shift in sentiment, although he believes there is still potential for net asset value compression [4] - The challenges of shorting crypto-related stocks are highlighted, with comparisons made to Tesla's overvaluation and the difficulties faced by short sellers in the crypto space [5][6]

Core Viewpoint - Qualigen Therapeutics Inc. will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025, and is launching new initiatives in the Web3 and crypto asset sectors [1] Group 1: Rebranding and New Initiatives - The company will officially change its name to AIxCrypto and introduce its new business initiatives in the crypto space [1] - AIxCrypto plans to launch the public beta of its BesTrade DeAI Agent by the end of November 2025 and release its EAI RWA Utility Token Whitepaper [2] Group 2: Strategic Goals - AIxCrypto aims to expand the C10 Treasury to $50 million in assets under management (AUM), having completed $12 million in crypto asset allocations as of October 17, 2025 [2] - The company intends to accelerate global growth of the BesTrade DeAI Agent, which will serve as a Meta Exchange optimizing transaction pathways and returns [3] - AIxCrypto plans to launch crypto ecosystem tokens on leading exchanges, supported by a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products [4] Group 3: Company Background - Qualigen Therapeutics, Inc. is a biotechnology company based in Carlsbad, California, focusing on innovative oncology and immunology therapies while expanding into crypto asset and Web3 strategies [5]

Regulatory Filing - Bitwise filed an S-1 with the SEC for a proposed spot Avalanche ETF [1] - The ETF aims to track $AVAX, Avalanche's native token [1] - Coinbase Custody would safeguard the assets [1] - The filing was submitted on September 15 [1] ETF Structure and Benefits - The ETF will provide investors access to Avalanche through standard brokerage accounts [2] - The trust will hold AVAX tokens outright and value them using the CME CF Avalanche-Dollar Reference Rate [2] - This structure mirrors spot Bitcoin and Ethereum ETFs [2] Market Competition and Institutional Interest - Grayscale has applied to convert its existing Avalanche Trust into a spot ETF [4] - VanEck is exploring its own AVAX fund [4] - Approval could bring traditional capital into Avalanche [4] - SkyBridge Capital has considered tokenizing $300 million worth of assets through Avalanche [4]

Crypto asset manager Bitwise files S-1 for Avalanche ETF https://t.co/Y32wcAVeYq ...

🔥 LATEST: Crypto asset manager CoinShares is set to go public on Nasdaq. https://t.co/sdivtNgaax ...

Crypto asset manager Grayscale submitted a registration statement for its Avalanche Trust, seeking to "uplist" the investment vehicle. https://t.co/YnKsEeUOix ...